Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
Lockman
Shahin
S
Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA 02115, USA. slockman@hsph.harvard.edu
McIntyre
James Alasdair
JA
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D024882:Drug Resistance, Viral / Q000187:drug effects*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use*; D011247:Pregnancy; D012367:RNA, Viral / Q000097:blood / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D004338:Drug Combinations; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine